A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
Public ClinicalTrials.gov record NCT01005901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Study identification
- NCT ID
- NCT01005901
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,324 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2009 (Type not available)
- Primary completion
- Dec 2010 (Actual)
- Completion
- Dec 2010 (Actual)
- Last update posted
- Apr 12, 2012
2009 – 2010
United States locations
- U.S. sites
- 33
- U.S. states
- 24
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | — | — |
| Novartis Investigative Site | Fairhope | Alabama | — | — |
| Novartis Investigative Site | Glendale | Arizona | — | — |
| Novartis Investigative Site | Los Angeles | California | — | — |
| Novartis Investigative Site | Walnut Creek | California | — | — |
| Novartis Investigative Site | Newark | Delaware | — | — |
| Novartis Investigative Site | Port Orange | Florida | — | — |
| Novartis Investigative Site | Tamarac | Florida | — | — |
| Novartis Investigative Site | Topeka | Kansas | — | — |
| Novartis Investigative Site | Madisonville | Kentucky | — | — |
| Novartis Investigative Site | Slidell | Louisiana | — | — |
| Novartis Investigative Site | Biddeford | Maine | — | — |
| Novartis Investigative Site | Pikesville | Maryland | — | — |
| Novartis Investigative Site | Ann Arbor | Michigan | — | — |
| Novartis Investigative Site | Livonia | Michigan | — | — |
| Novartis Investigative Site | Minneapolis | Minnesota | — | — |
| Novartis Investigative Site | Kansas City | Missouri | — | — |
| Novartis Investigative Site | Saint Charles | Missouri | — | — |
| Novartis Investigative Site | Missoula | Montana | — | — |
| Novartis Investigative Site | Bellevue | Nebraska | — | — |
| Novartis Investigative Site | Omaha | Nebraska | — | — |
| Novartis Investigative Site | Reno | Nevada | — | — |
| Novartis Investigative Site | New Brunswick | New Jersey | — | — |
| Novartis Investigative Site | Rochester | New York | — | — |
| Novartis Investigative Site | Cincinnati | Ohio | — | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | — | — |
| Novartis Investigative Site | Tulsa | Oklahoma | — | — |
| Novartis Investigative Site | Lincoln | Rhode Island | — | — |
| Novartis Investigative Site | Johnson City | Tennessee | — | — |
| Novartis Investigative Site | Corpus Christi | Texas | — | — |
| Novartis Investigative Site | McKinney | Texas | — | — |
| Novartis Investigative Site | San Antonio | Texas | — | — |
| Novartis Investigative Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01005901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2012 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01005901 live on ClinicalTrials.gov.